Lipaglyn™ (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the...
Verrica reports positive Phase III results of VP-102 in molluscum
Verrica Pharmaceuticals has reported positive results from the post-hoc pooled analysis of the Phase III CAMP clinical trials of VP-102 in patients with molluscum contagiosum.
AstraZeneca studies Fasenra in three new trials for skin diseases
AstraZeneca has started three new clinical trials to evaluate monoclonal antibody Fasenra for the treatment of eosinophil-driven skin diseases.
MAPS secures approval to expand MDMA therapy access for PTSD in US
Multidisciplinary Association for Psychedelic Studies (MAPS) has received US Food and Drug Administration (FDA) approval to expand access to 3,4-methylenedioxy-methamphetamine (MDMA)-based psychotherapy for post-traumatic stress disorder (PTSD).
Neuroptika enrols first patient for dry eye disease trial
Neuroptika has enrolled the first patient in a Phase II clinical trial of NRO-1 for the treatment of dry eye disease.
Emendo to invest in genetic engineering techniques
Gene editing firm Emendo Biotherapeutics has raised $61m through a Series B financing round led by AnGes, a Japanese biopharmaceutical company.
Euan MacDonald Centre launches motor neurone disease trials in UK
The Euan MacDonald Centre at the University of Edinburgh has launched a clinical drug trial for Motor Neurone Disease (MND).
Akero to expand ongoing Phase IIa trial of AKR-001 for NASH
Akero Therapeutics is set to expand the ongoing Phase IIa BALANCED study of Fc-FGF21 fusion protein AKR-001 to include an additional cohort of subjects with non-alcoholic steatohepatitis (NASH) who have compensated cirrhosis (F4), Child-Pugh Class A.
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn™ (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.
Elysium trial to study link between biological ageing and NAD+ levels
Life sciences firm Elysium Health has initiated a clinical trial at Duke Clinical Research Institute to study correlations between epigenetic age and circulating nicotinamide adenine dinucleotide (NAD+) levels in healthy adults.